- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dupilumab new treatment option for moderate-to-severe asthma in kids: NEJM
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
The findings of the international multicenter Liberty Asthma VOYAGE trial, reported Dec. 9 in the New England Journal of Medicine, supported approval of dupilumab for the treatment of moderate-to-severe asthma in this age group by the Food and Drug Administration in October.
"This is a really important advance for children with moderate-to-severe asthma and their families," said Leonard Bacharier, MD, an asthma specialist at Monroe Carell Jr. Children's Hospital at Vanderbilt and the international lead investigator for the trial.
Asthma -- a condition that affects the lung's airways and makes it hard to breathe -- is the most common chronic disorder of childhood, with more than 5 million children under age 18 affected, according to the Centers for Disease Control and Prevention. It is a leading cause of hospitalization for children, and children with moderate-to-severe asthma may have reduced lung function and be at greater risk for lung diseases in adulthood, said Bacharier, who holds the Janie Robinson and John Moore Lee Chair in Pediatrics at Vanderbilt University School of Medicine.
"As asthma gets increasingly severe, the burden becomes substantial, impacting the child and the entire family," he said. "While we have very good asthma therapies available, none of them are perfect in eliminating severe exacerbations."
Dupilumab, a monoclonal antibody that targets type 2 inflammation, has been approved for the treatment of asthma in adults and adolescents for several years. Based on its established safety and efficacy, the investigators conducted a phase 3 clinical trial in 408 children between the ages of 6 and 11 who had uncontrolled moderate-to-severe asthma
Children were randomized to receive a subcutaneous injection of dupilumab or placebo in addition to their standard therapy every two weeks for a year. Neither investigators nor participants knew who received active treatment versus placebo (double-blind trial design).
Most of the children in the trial had markers of type 2 inflammation, namely elevated levels of immune cells called eosinophils and/or elevated levels of nitric oxide in exhaled air. In patients with these markers, dupilumab significantly reduced the rate of severe exacerbations -- symptoms requiring systemic steroid treatment, need for emergency care or hospitalization -- by nearly 60%.
In addition, dupilumab improved lung function, measured by forced exhalation, and improved asthma control, assessed with standardized questionnaires administered by trained interviewers.
"This is the first study of its kind in children ages 6 to 11 that has demonstrated that a biologic improves asthma exacerbations, lung function and asthma control," Bacharier said. "We were not surprised, because dupilumab was very effective in clinical trials in adults and adolescents, but we were delighted with the results and the hope they bring to children and their families."
Dupilumab was not effective for the small number of children in the trial who did not have evidence of type 2 inflammation, consistent with expectations, he added.
The trial demonstrated that dupilumab was safe. Some children receiving active drug had increases in blood eosinophil levels or mild but manageable parasitic infections (type 2 immunity fights parasites), but very few participants had to discontinue dupilumab because of adverse reactions.
Patients in the VOYAGE trial were invited to join an extension trial for another year, with all participants receiving dupilumab. The extension trial will focus on both efficacy and long-term safety; results should be available in mid-2022.
Although two other biologic medicines targeting type 2 inflammation have been approved to treat asthma in children, neither has demonstrated improvements in all three key clinical endpoints -- asthma exacerbations, lung function and asthma control -- in a controlled clinical trial, Bacharier said.
Bacharier plans to explore the potential for dupilumab to modify asthma development. "Can we use this agent earlier in life to change how the disease develops? I think that's the next frontier," he said.
Bacharier is also a co-investigator of the PrecISE Network (Precision Interventions for Severe Asthma), a National Institutes of Health-funded network that is testing novel asthma therapies in patients with very severe asthma.
The Liberty Asthma VOYAGE trial (NCT02948959) was supported by Sanofi and Regeneron Pharmaceuticals, the manufacturers of dupilumab. Dupilumab is also FDA-approved for atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
https://www.nejm.org/doi/10.1056/NEJMoa2106567
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751